Switching from Apixaban to Edoxaban: Direct Transition Without Bridging
You can switch directly from apixaban to edoxaban without any bridging therapy—simply discontinue apixaban and start edoxaban at the time of the next scheduled apixaban dose. 1
How to Perform the Switch
Timing of the Switch
- Stop apixaban at its regularly scheduled time
- Start edoxaban at the exact time when the next apixaban dose would have been due
- No overlap period is needed
- No gap period is required
- No bridging with parenteral anticoagulation (heparin, LMWH) is necessary 1
Edoxaban Dosing After Switch
The standard edoxaban dose is 60 mg once daily, but dose reduction to 30 mg once daily is required if the patient has ANY of the following 2:
- Body weight ≤60 kg
- Creatinine clearance 30-50 mL/min (Cockcroft-Gault)
- Concomitant use of potent P-glycoprotein inhibitors (verapamil, quinidine, dronedarone)
Key Mechanistic Difference from Other Switches
Unlike switching to warfarin or dabigatran (which require parenteral bridging), edoxaban can be started immediately because:
- Both apixaban and edoxaban are factor Xa inhibitors with predictable pharmacokinetics
- Apixaban has a half-life of 9-14 hours 3
- Edoxaban reaches therapeutic levels within 1-2 hours 3
- Direct switching maintains continuous anticoagulation without gaps 4
Clinical Evidence Supporting Direct Switching
A pharmacokinetic study specifically evaluated switching from other DOACs to edoxaban 4. When healthy subjects switched from rivaroxaban to edoxaban at the time of the next dose:
- Edoxaban pharmacokinetic parameters were similar to edoxaban-only administration
- Coagulation status was maintained throughout the transition
- No safety concerns or increased bleeding risk occurred
- The switch was well tolerated
Important Caveats
Renal Function Monitoring
- Check creatinine clearance before switching to determine appropriate edoxaban dose
- Edoxaban is 50% renally cleared 5
- In severe renal impairment (CrCl 15-29 mL/min), edoxaban 30 mg daily is approved in Europe but use requires careful consideration 5
- Avoid edoxaban if CrCl >95 mL/min in atrial fibrillation patients—the EMA specifically warns that edoxaban should only be used in patients with high CrCl after careful evaluation, as efficacy may be reduced 5
Drug Interactions
- Avoid strong combined P-gp and CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort) with edoxaban 6
- If patient is on strong P-gp inhibitors, ensure dose reduction to 30 mg is applied 6
Clinical Context Considerations
- For VTE treatment: If switching during the initial treatment phase (first 5-10 days), note that edoxaban requires lead-in parenteral anticoagulation when starting fresh, but this does NOT apply when switching from another DOAC 2, 7
- For atrial fibrillation: Direct switch is appropriate at any time during chronic therapy 3, 8
Monitoring After Switch
- No routine coagulation monitoring is required
- Monitor for signs of bleeding or thrombosis clinically
- Check CBC if bleeding suspected
- Reassess renal function periodically, especially in elderly patients or those with baseline renal impairment 2
What NOT to Do
- Do not use parenteral bridging (this is only needed when switching TO warfarin or dabigatran, not when switching between factor Xa inhibitors) 1
- Do not overlap the medications (unlike warfarin transitions)
- Do not create a gap between stopping apixaban and starting edoxaban
- Do not double the first edoxaban dose
The simplicity of this switch reflects the pharmacologic similarity between these two factor Xa inhibitors and their rapid onset/offset of action, making direct substitution both safe and effective 4.